Q-omics provides the consensus-scored MIR6761 profile across patient tissues and cancer cell-line models. MIR6761 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR6761 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, MIR6761 RNA expression shows 6,974 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight HNSC, LUSC, and ESCA as cancer lineages where MIR6761 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6761 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6761 survival associations across molecular data types. MIR6761 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6761 RNA expression–survival associations across cancer types. High MIR6761 expression shows unfavorable associations in CHOL, STAD and ACC, but favorable associations in HNSC, MESO and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR6761 RNA expression.
This table summarizes MIR6761 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6761. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6761 shows lower tumor expression in LUSC and UCEC and higher tumor expression in COAD. The LUSC box plot shows higher MIR6761 RNA expression in normal versus tumor tissue (log2 FC = −0.386, t-test p < 0.001).
This table shows molecular features associated with MIR6761 in patient tissues and cancer cell lines. In patient samples, MIR6761 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
